Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR088 in Relapsed or Refractory Multiple Myeloma
NCT04322292Phase 1Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2019
- Primary completion
- Sep 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trovocabtagene autoleucel in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence of treatment-emergent adverse events at 30 days. Started Sep 2019; status: completed.
02
Drugs
trovocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04322292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322292.